Network biology in development of monoclonal antibody therapeutics

•In silico methods for the design of monoclonal antibody therapies were reviewed.•The translational focus of the network biology applications was highlighted.•Translational perspective of the use of mathematical modeling was addressed for development of antibodies.•Mathematical modeling in mAb development requires compilation of approaches and data at multiple levels to be successful.

Monoclonal antibodies (mAbs) are large glycoproteins that recognize and remove/neutralize a specific target. Inflammation and inflammatory diseases are often treated with mAb-based therapeutics. Mathematical modeling is widely used in development of mAbs. Bioinformatics and structural modeling is used for humanization of mAbs and PK/PD modeling is extensively used in preclinical and clinical development. The objective of this commentary is to introduce systems biology-based modeling that can accelerate and improve development of mAbs.